David Eugene Whitehead Jr, | |
2550 Belle Chasse Hwy Ste 150, Gretna, LA 70053-6733 | |
(504) 362-9010 | |
Not Available |
Full Name | David Eugene Whitehead Jr |
---|---|
Gender | Male |
Speciality | Case Manager/care Coordinator |
Location | 2550 Belle Chasse Hwy Ste 150, Gretna, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003490723 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TH0100X | Psychologist - Health Service | (* (Not Available)) | Secondary |
171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
David Eugene Whitehead Jr, 509 Fos Ave, Harvey, LA 70058-2715 Ph: (941) 724-4009 | David Eugene Whitehead Jr, 2550 Belle Chasse Hwy Ste 150, Gretna, LA 70053-6733 Ph: (504) 362-9010 |
News Archive
UNIST and Ulsan will initiate a research collaboration to develop human organs-on-chips in hoping to reduce the time and cost for new drug discovery.
A new study by UT Southwestern scientists indicates that an enzyme called protein phosphatase 2 (PP2A) appears to be a major driver of preeclampsia, a dangerous pregnancy complication characterized by the development of high blood pressure and excess protein in the urine.
Epocrates, Inc. today announced the pricing of the initial public offering of 5,360,000 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading today on the NASDAQ under the ticker symbol "EPOC." Epocrates is offering 3,574,285 shares and selling stockholders are offering the remaining 1,785,715 shares.
Therapeutic cancer vaccines, which stimulate the body's immune system to target and destroy cancer cells, are being used in combination with conventional chemotherapy with growing success, as described in several illuminating articles in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc.
› Verified 7 days ago